For years, PolyU has been committed to research in translational medicine leading to the involvement in developing the first three new drugs in Hong Kong that have gained Investigational New Drug status granted by the US Food and Drug Administration. Riding on the opportunity of biotechnology development in the Guangdong-Hong Kong-Macau Greater Bay Area, PolyU and Axis Therapeutics recently signed a Memorandum of Understanding to establish the PolyU—Axis Therapeutics Joint Center for Immunotherapy.
In this collaboration between academic and industry, the Centre will focus on the research, development and commercialisation of T-cell receptor-engineered T cells (TCR-T) and Chimeric Antigen Receptor-engineered T-cells (CAR-T) based cancer immunotherapy technologies. It is expected that the synergy will complement existing related research to benefit patients in Hong Kong and beyond. Details>>